6 results on '"Konno, R."'
Search Results
2. The need for public education on HPV and cervical cancer prevention in Asia
- Author
-
Garland, S., primary, Park, S.N., additional, Ngan, H.Y.S., additional, Frazer, I., additional, Tay, E.H., additional, Chen, C.J., additional, Bhatla, N., additional, Pitts, M., additional, Shin, H.R., additional, Konno, R., additional, Smith, J., additional, Pagliusi, S., additional, and Park, J.S., additional
- Published
- 2008
- Full Text
- View/download PDF
3. Effectiveness of HPV vaccination against high grade cervical lesions in Japan.
- Author
-
Konno R, Konishi H, Sauvaget C, Ohashi Y, and Kakizoe T
- Subjects
- Adult, Cohort Studies, Female, Humans, Japan, Mass Screening, Regression Analysis, Uterine Cervical Neoplasms diagnosis, Vaccine Potency, Young Adult, Uterine Cervical Dysplasia diagnosis, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use, Uterine Cervical Neoplasms prevention & control, Vaccination statistics & numerical data, Uterine Cervical Dysplasia prevention & control
- Abstract
The effectiveness of HPV vaccine against HSIL+ (pathologically diagnosed CIN2+) in the first cohort in Japan was investigated in 22,743 women aged 20 to 29 years (parts of national cervical cancer screening program of FY [fiscal year] 2015, the Japan Cancer Society). Vaccinated women had a statistically significant 69% lower risk of HSIL+ as compared to the unvaccinated women; the crude relative risk estimate was 0.31 (95% CI: 0.11-0.83; p-value = 0.013) by normal approximation and 0.31 (95% CI: 0.08-0.80; p-value = 0.009) by the exact Poisson regression. The effect of age was not significant (chisq = 7.7 (df = 9), p-value = 0.569) and the estimate of relative risk remained essentially intact after adjustment for age. This study brings scientific evidence on the effectiveness of HPV vaccine on development of cervical high grade lesions., (Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
4. Acceptance of and attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls.
- Author
-
Hanley SJ, Yoshioka E, Ito Y, Konno R, Hayashi Y, Kishi R, and Sakuragi N
- Subjects
- Adolescent, Adult, Asian People, Child, Demography, Female, Humans, Japan, Middle Aged, Papillomavirus Infections prevention & control, Surveys and Questionnaires, Vaccination economics, Health Knowledge, Attitudes, Practice, Mothers psychology, Papillomavirus Vaccines economics, Patient Acceptance of Health Care statistics & numerical data, Vaccination psychology
- Abstract
To better understand how to achieve high uptake rates of human papillomavirus (HPV) vaccination in Japan, we investigated acceptance of and attitudes towards HPV vaccination in 2192 mothers of girls aged 11-14 yrs. A school-based survey was conducted in five elementary and fourteen junior high schools in Sapporo, Japan. Responses from 862 participants were analyzed. Ninety-three percent of mothers would accept the vaccine for their daughter if free, but only 1.5% was willing to pay the minimum recommended price of ¥ 40,000. Vaccine acceptance was higher in mothers who had heard of HPV vaccine (adjusted odds ratio, aOR=2.58, confidence interval, CI=1.47-4.53), and who believed susceptibility to (aOR=2.30, CI=1.34-3.92) and severity of (aOR=3.73, CI=1.41-9.88) HPV to be high. Recommendations from a doctor (aOR=12.60, CI=7.06-21.48) and local health board (aOR=27.80, CI=13.88-55.86) were also positively associated with increased HPV vaccine acceptance. Concerns about side effects of both the HPV vaccine (aOR=0.03, CI=0.01-0.08) and routine childhood vaccines in general (aOR=0.11, CI=0.02-0.78) emerged as barriers to vaccination. Not participating in routine cervical screening also emerged as a deterrent (aOR=0.49, CI=0.27-0.91). While most mothers (66.8%) agreed that 10-14 yr was an appropriate age for vaccination, a further 30.6% believed >15 yr to be more appropriate. In conclusion, attitudes of Japanese mothers toward HPV vaccination are encouraging. While lower vaccine acceptance in mothers who do not undergo regular cervical screening needs further investigation, this study indicates that high uptake may be possible in a publically funded HPV vaccination program if physicians actively address safety concerns and justify why the vaccine is needed at a particular age., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
5. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
- Author
-
Konno R, Shin HR, Kim YT, Song YS, Sasagawa T, Inoue M, and Park JS
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma in Situ mortality, Carcinoma in Situ virology, Child, Child, Preschool, DNA, Viral isolation & purification, Early Detection of Cancer, Female, Guidelines as Topic, Human papillomavirus 16 isolation & purification, Human papillomavirus 18 isolation & purification, Humans, Incidence, Infant, Japan epidemiology, Korea epidemiology, Middle Aged, Papillomavirus Infections complications, Papillomavirus Infections diagnosis, Papillomavirus Infections pathology, Papillomavirus Vaccines therapeutic use, Prevalence, Risk Factors, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms virology, Vaccination, Vaginal Smears, Young Adult, Carcinoma in Situ diagnosis, Carcinoma in Situ prevention & control, Mass Screening, Papillomavirus Infections epidemiology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms prevention & control
- Abstract
Cervical cancer is a common cancer among women in Japan and Korea. Implementation of national cervical cancer screening programs has led to a reduction in the incidence of cervical cancer in both countries. However, over the past decade, there has been a recent marked increase in cervical cancer incidence among young women in Japan. Human papillomavirus (HPV) is found in the majority of cervical cancers, and HPV-16 and 18 are the two most common types. The next most frequent HPV types in cervical cancer are 52, 58 and 33 for Japan and 52, 58, and 33 for Korea, varying slightly when compared to the worldwide distribution. Screening coverage for both countries remains a challenge. Current coverage is reported at 24% in Japan, with the lowest coverage in young Japanese women, and 41% in Korea. Cytology remains the predominant screening method. HPV DNA testing is widely used to triage women with abnormal cytology in Korea. HPV vaccines have been licensed in Korea, but not yet in Japan. In both countries cost is a substantial impediment to implementation and no national programs are currently planned or in place. Therefore, increased disease awareness and utilization of screening is the first priority for controlling cervical cancer.
- Published
- 2008
- Full Text
- View/download PDF
6. Recommendations for cervical cancer prevention in Asia Pacific.
- Author
-
Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, and Bosch FX
- Subjects
- Adolescent, Adult, Aged, Alphapapillomavirus classification, Alphapapillomavirus isolation & purification, Asia epidemiology, Cost-Benefit Analysis, Female, Humans, Immunization Programs, Male, Mass Screening, Middle Aged, Pacific Islands epidemiology, Papillomavirus Infections complications, Papillomavirus Infections epidemiology, Papillomavirus Vaccines economics, Papillomavirus Vaccines standards, Prevalence, Risk Factors, Treatment Outcome, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms etiology, Vaccination economics, Vaccination standards, Vaginal Smears, Young Adult, Health Planning Guidelines, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use, Uterine Cervical Neoplasms prevention & control
- Abstract
Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.